Oculis Holding AG
OCSDrugs in Pipeline
7
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Dec 15, 2026
33wMarket Overview
Stock performance and key metrics
1 upcoming, 2 past
Dexamethasone ophthalmic suspension (OCS-01)
Diabetic Macular Edema
Vehicle
Diabetic Macular Edema
OCS-01
Inflammation Eye Pain
licaminlimab
Dry Eye Disease
Dexamethasone nanoparticles eye drops
Diabetic Macular Edema
OCS-05 +SoC (corticosteroid) IV administration
Optic Neuritis
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL
Inflammation Corneal
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Dexamethasone ophthalmic suspension (OCS-01) | Phase 3 | Diabetic Macular Edema | - | - |
Vehicle | Phase 3 | Diabetic Macular Edema | - | - |
OCS-01 | Phase 3 | Inflammation Eye Pain | - | - |
licaminlimab | Phase 3 | Dry Eye Disease | - | - |
Dexamethasone nanoparticles eye drops | Phase 2 | Diabetic Macular Edema | - | - |
OCS-05 +SoC (corticosteroid) IV administration | Phase 2 | Optic Neuritis | - | - |
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL | Phase 2 | Inflammation Corneal | - | - |